BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/2/2024 3:28:29 AM | Browse: 120 | Download: 0
Category |
Oncology |
Manuscript Type |
Retrospective Study |
Article Title |
Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Xiao-Ting Ma, Kai Ou, Wen-Wei Yang, Bi-Yang Cao and Lin Yang |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Beijing CSCO Clinical Oncology Research Foundation |
No. Y-HH202102-0314 |
|
Corresponding Author |
Lin Yang, MD, Director, Director, Doctor, Doctor, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. linyangcicams@126.com |
Key Words |
First line; Gastric cancer; Human epidermal growth factor receptor 2; Programmed cell death protein 1; Progression-free survival |
Core Tip |
For when considering non-positive human epidermal growth factor receptor 2 (HER2) advanced gastric cancer (AGC), combined positive score and HER2 expression are represent influencing factors for the treatment efficacy of AGC patients receiving immunotherapy combined with chemotherapy. Survival analysis with When using progression-free survival (PFS) as the end point, survival analysis suggested that the HER2 expression level was levels are suggestive of the efficacy of treatment featuring a programmed cell death protein 1 inhibitor combined with and chemotherapy. With the increase of HER2 expression, PFS also showed a tendency to prolong increase with an increase in HER2 expression. |
Citation |
<p>Ma XT, Ou K, Yang WW, Cao BY, Yang L. Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer. <i>World J Clin Oncol</i> 2024; 15(5): 635-643</p> |
|
Received |
|
2024-01-02 16:17 |
|
Peer-Review Started |
|
2024-01-02 16:17 |
|
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-01-22 05:51 |
|
Revised |
|
2024-02-08 21:38 |
|
Second Decision |
|
2024-04-02 02:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-02 03:28 |
|
Articles in Press |
|
2024-04-02 03:28 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-09 00:33 |
ISSN |
2218-4333 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345